Clin2
NCT05875168Worth exploringRecruiting

Study of DS-3939a for Advanced Solid Tumors

Advanced Solid TumorMetastatic Solid Tumor

Part of Cancer clinical trials.

This trial is testing a new drug called DS-3939a for people with advanced solid tumors that have not responded to other treatments. The study has two parts to find the right dose and see how well it works.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
590 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must sign a consent form.
  • Your heart function must be normal (ejection fraction of 50% or more).
  • Your organs must be working well enough.
  • Your tumors must be measurable on scans.
  • You must be able to take care of yourself (ECOG score 0 or 1).
  • You must have a tumor sample (either a fresh biopsy or an old one from the last 6 months).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07182591Recruiting· Phase 1
Study of DS5361b for advanced solid tumors with high TMB or MSI

This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.

Sarasota, Florida
NCT05765851Recruiting· Phase 1
HER2-targeting drug study for advanced solid tumors

This Phase 1 trial tests a combination of medicines (including DS-1103a) for people with advanced, hard-to-remove (unresectable) or metastatic solid tumors that have HER2 changes. Because it’s an early safety/dose study, it mainly aims to find the right dose and see how the tumor responds.

Sarasota, Florida
NCT07681882Recruiting· Phase 1
Testing DS1025a in people with advanced solid tumors

This trial tests a new drug, DS1025a, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.

Kashiwa
NCT07667842Not yet recruiting· Phase 1
Study of D3L-002 for advanced solid tumors

This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.

NCT07086768Recruiting· Phase 1
BSI-082 alone or with T-DXd for advanced solid tumors

This trial tests a new drug, BSI-082, alone or with another drug (T-DXd), for people with advanced solid tumors that no longer respond to standard therapy. It aims to find the best dose and check how well it works.

San Antonio, Texas
NCT07739966Not yet recruiting· Phase 1/Phase 2
Study of DS-3939a for advanced solid tumors

This trial tests a new drug called DS-3939a for people with advanced solid tumors, especially a type of lung cancer. The drug targets a protein on cancer cells to try to shrink tumors or slow their growth.

Hear when a new Advanced Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.